期刊文献+

论无过错输血感染的责任认定

The liability cognizance of non-default transfusion infection
原文传递
导出
摘要 输血感染是医疗机构临床用血所面临的一大困境,尤其是因某些危险因素的窗口期导致的无过错输血感染,并非医疗机构及其医务人员的过错,而是受到了当前医疗技术水平的限制,《侵权责任法》对这类输血感染并未做出区分,一律适用了严格责任,并不符合医疗活动的实际状况,也不能真正起到缓解医患矛盾的作用。而对临床输血以是否符合法律、法规和相关诊疗规范为标准进行区分,将窗口期引起的无过错输血感染排除在医方的责任以外,通过补偿制度或第三方保险来解决,才是实现医患之间实质公平的途径。 The predicament faced by clinical blood use in medical institutions is blood transfusion infection, es- pecially some of the risk factors cause the non-default transfusion infection in window period. It is not the fault of the medical institutions and their staff, but the restriction of current level of medical technology. Tort Liability Act do not make distinctions between the default and non-default blood transfusion infection, which is not consistent with the facts and cannot really relieve medical dispute. The way to solve this problem is to put the non-default transfusion infection caused by window period out of the responsibility of hospital. Instead, we can resolve the prob- lem via compensation system or third-party insurance.
作者 杨智超
机构地区 广西大学法学院
出处 《中国卫生法制》 2013年第2期52-54,共3页 China Health Law
关键词 无过错输血感染 严格责任 窗口期 Non-default transfusion infection Strict liability Window period
  • 相关文献

参考文献3

二级参考文献21

  • 1高峰,Ma-N.,H.有机溶剂/去污剂病毒灭活技术在静脉注射免疫球蛋白制备中的应用[J].上海医学,1994,17(1):18-21. 被引量:1
  • 2Pau CP, Hu DJ, Spruill C, et al. Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion, 1996, 36(5): 398-400.
  • 3Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis, 1993, 168 (6): 1490-1501.
  • 4Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med, 1997, 102(5B): 117-124, discussion 125-126.
  • 5Murthy KK, Henrard DR, Eichberg JW, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion, 1999, 39(7): 688-693.
  • 6Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 2002, 42(8): 975-979.
  • 7Kopko PM, Fernando LP, Bonney EN, et al. HIV transmissions from a window-period platelet donation. Am J Clin Pathol, 2001, 116(4): 562-566.
  • 8Wendel S, Fachini RM, Levi JE, et al. A single windowperiod donation detected by human immunodeficiency virus p24 antigen after 5 years of routine screening in a group of Brazilian blood banks. Vox Sang,2002, 83(4): 309-312.
  • 9Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA, 2000, 284(2): 210-214.
  • 10Icardi G, Ansaldi F, Bruzzone BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period:clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol, 2001, 39(9): 3110-3114.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部